# Investigation of the NVT ALLEGRA Plus THV System in Patients With Severe Aortic Stenosis or Failed Surgical Aortic Bioprosthesis

Study · id `cardio:ct-nct05804903` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05804903](<https://clinicaltrials.gov/study/NCT05804903>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05804903

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is suspended. It plans to enroll 177 participants.

## Technical summary

Registry record NCT05804903. Allocation not applicable; no masking; primary purpose treatment. Start 2023-11-24 (actual); primary completion 2025-08-31 (actual). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 177 participants (planned count; ClinicalTrials.gov record NCT05804903, source copy `cardio:ctgov-nct05804903-2026-03-09`, retrieved 2026-10-26)
- Started: 2023-11-24 (actual) (ClinicalTrials.gov record NCT05804903, source copy `cardio:ctgov-nct05804903-2026-03-09`, retrieved 2026-10-26)
- Primary completion: 2025-08-31 (actual) (ClinicalTrials.gov record NCT05804903, source copy `cardio:ctgov-nct05804903-2026-03-09`, retrieved 2026-10-26)
- Completion: 2030-08-01 (anticipated) (ClinicalTrials.gov record NCT05804903, source copy `cardio:ctgov-nct05804903-2026-03-09`, retrieved 2026-10-26)
- Countries: Finland; Germany; Poland; Spain; Switzerland (ClinicalTrials.gov record NCT05804903, source copy `cardio:ctgov-nct05804903-2026-03-09`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "SUSPENDED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05804903-2026-03-09`, retrieved 2026-10-26)

## The registry's words

- Brief title: Investigation of the NVT ALLEGRA Plus THV System in Patients With Severe Aortic Stenosis or Failed Surgical Aortic Bioprosthesis
- Acronym: EMPIRE-II
- Condition: Transcatheter Aortic Valve Implantation
- Intervention (Device): (ALLEGRA Plus Transcatheter Heart Valve) TAVI in severe calcified aortic stenosis or in failed surgical aortic bioprosthesis
- Lead sponsor: NVT GmbH
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Aortic stenosis (`cardio:aortic-stenosis`)
- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)

## Provenance

Content hash: a8b2fa823df4cce659d7a0b7d19633151d76e65311b97879a230ee2ca4547e22
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
